 |
20 Diseases |  |
19 Trials |
|
19 Trials |  |
1670 News |  |
| «12...78910111213141516171819» |
- | Zykadia (ceritinib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 22, 2017
P1, N=96, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jun 2017 --> Sep 2017
- | Zykadia (ceritinib) / Novartis, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Jun 20, 2017
P1/2, N=30, Not yet recruiting, Sponsor: University of Washington
Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Jul 2020 --> Feb 2023
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Combination therapy: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 20, 2017
P1, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2020 --> Feb 2023 Trial primary completion date: Oct 2017 --> Aug 2018
- | Biomarker, Journal: Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (Pubmed Central) - Jun 18, 2017
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Journal: Emerging Treatment for ALK-positive Lung Cancer. (Pubmed Central) - May 31, 2017
However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: Ascend-7: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (clinicaltrials.gov) - May 23, 2017
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors. Trial primary completion date: May 2018 --> Dec 2018
- | Alecensa (alectinib) / Roche
Journal: The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. (Pubmed Central) - May 12, 2017
Expert commentary: Second generation ALK inhibitors as alectinib and ceritinib can overcome crizotinib-resistant mutations and improve central nervous system control. Novel third-generation inhibitors and combination of agents give hope of achieving an even longer disease control in the next decade.
- ||| Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Trial initiation date, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 8, 2017
P1/2, N=69, Not yet recruiting, Sponsor: University of California, San Francisco
Novel third-generation inhibitors and combination of agents give hope of achieving an even longer disease control in the next decade. Initiation date: Mar 2017 --> Jun 2017
- | Zykadia (ceritinib) / Novartis, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Mar 29, 2017
P1/2, N=30, Not yet recruiting, Sponsor: University of Washington
Initiation date: Mar 2017 --> Jun 2017 Initiation date: Dec 2016 --> Jun 2017
- Zykadia (ceritinib) / Novartis
Trial primary completion date: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Mar 28, 2017
P2, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2016 --> Jun 2017 Trial primary completion date: Nov 2017 --> Aug 2017
- | Zykadia (ceritinib) / Novartis
Trial primary completion date: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Mar 27, 2017
P2, N=32, Recruiting, Sponsor: Yonsei University
Trial primary completion date: Nov 2017 --> Aug 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Trial initiation date, PARP Biomarker, Metastases: MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 23, 2017
P4, N=1000, Not yet recruiting, Sponsor: Melanoma Institute Australia
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Mar 2017 --> Jun 2017
- ||||| Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
New P1/2 trial, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 22, 2017
P1/2, N=69, Not yet recruiting, Sponsor: University of California, San Francisco
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 3, 2017
P1, N=318, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2017 --> Jun 2017 Trial primary completion date: Jan 2018 --> Oct 2018
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Mar 1, 2017
P1/2, N=103, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2018 --> Oct 2018 Trial primary completion date: Dec 2016 --> Jun 2017
- Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors (clinicaltrials.gov) - Feb 28, 2017
P1, N=35, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Feb 2017 --> Sep 2017
- Zykadia (ceritinib) / Novartis
Enrollment change, Trial withdrawal: Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies (clinicaltrials.gov) - Feb 1, 2017
P2, N=0, Withdrawn, Sponsor: Anne Beaven, MD
Trial primary completion date: Feb 2017 --> Sep 2017 N=24 --> 0 | Recruiting --> Withdrawn
- | Zykadia (ceritinib) / Novartis
Trial completion, Trial primary completion date: Effect of Hepatic Impairment on LDK378 Pharmacokinetics (clinicaltrials.gov) - Dec 14, 2016
P1, N=36, Completed, Sponsor: Novartis Pharmaceuticals
N=24 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: Jan 2017 --> Sep 2016
- Zykadia (ceritinib) / Novartis
Trial primary completion date: Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis (clinicaltrials.gov) - Dec 13, 2016
P0, N=48, Recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Recruiting --> Completed | Trial primary completion date: Jan 2017 --> Sep 2016 Trial primary completion date: Nov 2016 --> Jun 2017
- | Zykadia (ceritinib) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Nov 29, 2016
P2, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2016 --> Jun 2017 Recruiting --> Completed | N=90 --> 45 | Trial primary completion date: Mar 2018 --> Sep 2016
- Trial initiation date, PARP Biomarker, Metastases: MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) - Nov 10, 2016
P4, N=1000, Not yet recruiting, Sponsor: Melanoma Institute Australia
Recruiting --> Completed | N=90 --> 45 | Trial primary completion date: Mar 2018 --> Sep 2016 Initiation date: Jun 2016 --> Mar 2017
- Zykadia (ceritinib) / Novartis
Trial primary completion date: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Nov 1, 2016
P2, N=32, Recruiting, Sponsor: Yonsei University
Initiation date: Jun 2016 --> Mar 2017 Trial primary completion date: Sep 2015 --> Dec 2016
- || Zykadia (ceritinib) / Novartis
Trial initiation date: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Oct 17, 2016
P1, N=105, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2015 --> Dec 2016 Initiation date: Feb 2013 --> Aug 2013
- Zykadia (ceritinib) / Novartis, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Sep 27, 2016
P1/2, N=30, Not yet recruiting, Sponsor: University of Washington
Initiation date: Feb 2013 --> Aug 2013 Initiation date: Jul 2016 --> Dec 2016
- || Zykadia (ceritinib) / Novartis
Trial primary completion date: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Sep 21, 2016
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2016 --> Dec 2016 Trial primary completion date: Sep 2018 --> Mar 2018
- ||| Zykadia (ceritinib) / Novartis
Enrollment change, Metastases: Ascend-7: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (clinicaltrials.gov) - Sep 21, 2016
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2018 --> Mar 2018 N=125 --> 160
- Zykadia (ceritinib) / Novartis
Trial primary completion date: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Sep 12, 2016
P2, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
N=125 --> 160 Trial primary completion date: Apr 2018 --> Nov 2017
- || Zykadia (ceritinib) / Novartis
Trial initiation date, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 12, 2016
P1, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2018 --> Nov 2017 Initiation date: Jan 2015 --> Apr 2015
- || Zykadia (ceritinib) / Novartis
Trial primary completion date: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - Sep 2, 2016
P2, N=126, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2015 --> Apr 2015 Trial primary completion date: Nov 2016 --> Jun 2017
- Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors (clinicaltrials.gov) - Aug 8, 2016
P1, N=35, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2016 --> Jun 2017 Trial primary completion date: Aug 2016 --> Nov 2016
- || Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 8, 2016
P2, N=85, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2016 --> Nov 2016 Trial primary completion date: Dec 2017 --> Apr 2018
- ||| Zykadia (ceritinib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment open: NEPENTHE: Next Generation Personalized Neuroblastoma Therapy (clinicaltrials.gov) - Jul 28, 2016
P1, N=83, Recruiting, Sponsor: Yael P Mosse
Trial primary completion date: Dec 2017 --> Apr 2018 Not yet recruiting --> Recruiting
- ||| Zykadia (ceritinib) / Novartis
Enrollment change: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Jul 1, 2016
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=70 --> 90
- ||| Zykadia (ceritinib) / Novartis
Biomarker, Enrollment open, Combination therapy, Metastases: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 23, 2016
P1, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=70 --> 90 Not yet recruiting --> Recruiting
- | Zykadia (ceritinib) / Novartis
Trial completion, Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 10, 2016
P1, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016
- Zykadia (ceritinib) / Novartis
Enrollment open: Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis (clinicaltrials.gov) - May 26, 2016
P0, N=48, Recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016 Not yet recruiting --> Recruiting
- ||| Zykadia (ceritinib) / Novartis, Kisqali (ribociclib) / Novartis
New P1 trial: NEPENTHE: Next Generation Personalized Neuroblastoma Therapy (clinicaltrials.gov) - May 23, 2016
P1, N=83, Not yet recruiting, Sponsor: Yael P Mosse
- Enrollment closed, Trial initiation date, Trial primary completion date: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma (clinicaltrials.gov) - May 16, 2016
P2, N=44, Active, not recruiting, Sponsor: Adil Daud
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Zykadia (ceritinib) / Novartis
Enrollment closed: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - May 3, 2016
P3, N=374, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting | Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- ||||| Zykadia (ceritinib) / Novartis
Enrollment closed, Metastases: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (clinicaltrials.gov) - Apr 26, 2016
P3, N=230, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=85, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Dec 2017
- |||| Zykadia (ceritinib) / Novartis
Enrollment open, Metastases: Ceritinib Rare Indications Study in ALK+ Tumors (clinicaltrials.gov) - Apr 22, 2016
P2, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| Zykadia (ceritinib) / Novartis
Trial completion: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (clinicaltrials.gov) - Apr 12, 2016
P2, N=141, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Zykadia (ceritinib) / Novartis, Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P1/2 trial: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=30, Not yet recruiting, Sponsor: University of Washington
- | Zykadia (ceritinib) / Novartis
Enrollment open: Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies (clinicaltrials.gov) - Mar 25, 2016
P2, N=30, Recruiting, Sponsor: Criterium, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial initiation date, Trial primary completion date, PARP Biomarker, Metastases: MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 24, 2016
P4, N=1000, Not yet recruiting, Sponsor: Melanoma Institute Australia
Not yet recruiting --> Recruiting Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Mar 2021 --> Jun 2021
- || Zykadia (ceritinib) / Novartis
Trial initiation date, Trial primary completion date, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 14, 2016
P1, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Mar 2021 --> Jun 2021 Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2017 --> Jan 2018
- | Zykadia (ceritinib) / Novartis
Trial completion: Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Mar 8, 2016
P1, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2017 --> Jan 2018 Active, not recruiting --> Completed
- Zykadia (ceritinib) / Novartis
Trial primary completion date: Effect of Hepatic Impairment on LDK378 Pharmacokinetics (clinicaltrials.gov) - Feb 29, 2016
P1, N=32, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jan 2017
- |||| Zykadia (ceritinib) / Novartis
Enrollment open: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (clinicaltrials.gov) - Feb 12, 2016
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting